390 related articles for article (PubMed ID: 21724302)
21. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
22. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
23. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
24. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
25. Ropinirole and pramipexole, the new agonists.
Hobson DE; Pourcher E; Martin WR
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
[TBL] [Abstract][Full Text] [Related]
26. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
27. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
[TBL] [Abstract][Full Text] [Related]
28. Role of dopamine agonists in Parkinson's disease: an update.
Bonuccelli U; Pavese N
Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
[TBL] [Abstract][Full Text] [Related]
29. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
[TBL] [Abstract][Full Text] [Related]
30. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
[TBL] [Abstract][Full Text] [Related]
31. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
32. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel MD
Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
34. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
35. Othello syndrome in patients with Parkinson's disease.
Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
[TBL] [Abstract][Full Text] [Related]
36. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
37. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
38. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Taguchi S; Koide H; Oiwa H; Hayashi M; Ogawa K; Ito C; Nakashima K; Yuasa T; Yasumoto A; Ando H; Fujikake A; Fukuoka T; Tokui K; Izumi M; Tsunoda Y; Kawagashira Y; Okada Y; Niwa JI; Doyu M
PLoS One; 2021; 16(7):e0255274. PubMed ID: 34320022
[TBL] [Abstract][Full Text] [Related]
39. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.
Chen XT; Zhang Q; Chen FF; Wen SY; Zhou CQ
Front Neurol; 2023; 14():1183823. PubMed ID: 37396766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
